A Study to Assess the Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in the Treatment of Operable Breast Cancer
The investigators select 60 cases of women with breast cancer at clinical stage of
T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500
mg/m2, 21day/cycle) as neoadjuvant chemotherapy. Finally the investigators assess the
efficacy and safety of Albumin-bound Paclitaxel.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
therapeutic assessment
therapeutic assessment
6 months
Yes
Jin Zhang, Professor
Study Chair
Tianjin Cancer hospital
China: Ministry of Health
aesa
NCT01647672
January 2012
December 2013
Name | Location |
---|